Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

30
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
30

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Potential Deployment Strategies for Oral Delivery of Vaccines for Cervids.

Transboundary and emerging diseases·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Nonawake versus Awake Placement of Spinal Cord Stimulators in Canada.

The Neurodiagnostic journal·2025
Same author

Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity.

PloS one·2025
Same author

H3K27M-mutant spinal cord and hemispheric tumor with prolonged survival: illustrative case.

Journal of neurosurgery. Case lessons·2025
Same journal

Tracking Synthetic Adhesins on Bacterial Surfaces with Immunofluorescence Microscopy.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Post-Selection Methods for Analyzing mRNA Display Selections and Optimization of Hits.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

High-Performance Computing in Tandem Mass Spectrometry (MS/MS) Peptide Identification.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Engineering and Adapting Disulfide-Containing Proteins to Enable Intracellular Functionality.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

AI-Driven Protein Research: From Prediction to Design.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Methods for the In Vitro Selection of Protein and Peptide Libraries Using mRNA Display.

Methods in molecular biology (Clifton, N.J.)·2026
See all related articles

Related Experiment Video

Updated: Mar 22, 2026

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay
11:41

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay

Published on: March 10, 2015

8.3K

Methods and Protocols for Developing Prion Vaccines.

Kristen Marciniuk1,2, Ryan Taschuk1,2,3, Scott Napper4,5

  • 1Department of Biochemistry, University of Saskatchewan, Saskatoon, SK, Canada, S7N 5E5.

Methods in Molecular Biology (Clifton, N.J.)
|April 15, 2016
PubMed
Summary
This summary is machine-generated.

Developing prion disease vaccines requires targeting misfolded prion protein (PrPSc) using disease-specific epitopes (DSEs). This approach aims to induce immunity against the infectious form while sparing the normal protein (PrPC).

Keywords:
Conformation-specific vaccinesDisease-specific epitopesImmunotherapyPrion diseaseProteinopathiesVaccine

More Related Videos

Procedures for Identifying Infectious Prions After Passage Through the Digestive System of an Avian Species
12:00

Procedures for Identifying Infectious Prions After Passage Through the Digestive System of an Avian Species

Published on: November 6, 2013

11.7K
Protein Misfolding Cyclic Amplification of Prions
10:12

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

20.3K

Related Experiment Videos

Last Updated: Mar 22, 2026

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay
11:41

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay

Published on: March 10, 2015

8.3K
Procedures for Identifying Infectious Prions After Passage Through the Digestive System of an Avian Species
12:00

Procedures for Identifying Infectious Prions After Passage Through the Digestive System of an Avian Species

Published on: November 6, 2013

11.7K
Protein Misfolding Cyclic Amplification of Prions
10:12

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

20.3K

Area of Science:

  • Neuroscience and Immunology
  • Protein Misfolding Diseases
  • Vaccine Development

Background:

  • Prion diseases involve the misfolding of cellular prion protein (PrPC) into an infectious PrPSc form.
  • Vaccine development is challenging due to the risk of immune responses against self-proteins.
  • Targeting the misfolded PrPSc conformation offers a promising avenue for specific immunotherapy.

Purpose of the Study:

  • To explore strategies for developing conformation-specific prion vaccines.
  • To identify and utilize disease-specific epitopes (DSEs) exclusively presented by PrPSc.
  • To outline the steps needed to translate DSEs into effective and safe prion vaccines.

Main Methods:

  • Identification of unique epitopes on the misfolded PrPSc conformation.
  • Optimization of DSE sequences to enhance immunogenicity and overcome self-tolerance.
  • Development of effective formulation and delivery systems for peptide-based vaccines.

Main Results:

  • Disease-specific epitopes (DSEs) offer a strategy for conformation-specific prion immunotherapy.
  • Successful vaccine development requires overcoming poor immunogenicity of self-proteins and short peptides.
  • Vaccine candidates must demonstrate specificity for PrPSc over PrPC and ensure safety against antibody-induced misfolding.

Conclusions:

  • Translating DSEs into functional prion vaccines necessitates significant optimization of immunogenicity and delivery.
  • Careful evaluation of specificity and safety is critical for successful DSE-based prion vaccine development.
  • This approach holds potential for clearing or neutralizing infectious prion isomers while preserving normal protein function.